NanOlogy touted results today from preclinical studies of its inhaled submicron particle formulation of paclitaxel, NanoPac. The company said animal studies have shown prolonged retention of the cancer drug in lung tissue and significant tumor regression without adverse drug-related side effects. NanOlogy plans to present the data from its preclinical studies at this year’s annual […]
NanOlogy looks to transform chemotherapy with localized delivery platform
Paclitaxel revolutionized cancer treatment when it was first used as a chemotherapeutic in the 1990s. But although the product is a powerful cancer killer, patients taking systemic doses of paclitaxel have to endure side effects such as peripheral neuropathy and hair loss. Marc Iacobucci and his team at NanOlogy believe they could replace the need […]
NanOlogy takes nanoparticle tech into Phase II trials
In the last two weeks, NanOlogy has launched trials evaluating its cancer-fighting paclitaxel nanoparticle suspension in patients with prostate cancer and in patients with ovarian cancer. The Texas-based company’s nanoparticle tech is based on a production process that cuts the size of chemotherapy crystals by up to 400 times, creating stable nanoparticles with increased surface […]
